For GC patients, the heterogeneity of HER2 status not only influences the accurate interpretation of HER2 status, but also associates with the treatment efficacy of anti-HER2 therapy (Wakatsuki et al., 2018; Yagi et al., 2019). This evidence concerns the gene ERBB2 and gastric cancer.